LIXT
Lixte Biotechnology Holdings Inc

3,587
Loading...
Loading...
News
all
press releases
12 titres de soins de sant en mouvement lors de la pr -ouverture le 27/03/2024
Gagnants Le titre Lixte Biotechnology (NASDAQ:LIXT) a mont mercredi de 64,07% 3,70 dollars lors de la session pre-market. L'action Nutriband (NASDAQ:NTRB) a mont de 29,92% 3,95...
Benzinga·2y ago
News Placeholder
More News
News Placeholder
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE...
Globe Newswire·2y ago
News Placeholder
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( LIXTE or...
Globe Newswire·2y ago
News Placeholder
Professor Ren Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research
Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic PASADENA, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology...
Globe Newswire·2y ago
News Placeholder
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Agreement Focuses on Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...
Globe Newswire·2y ago
News Placeholder
First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ( LIXTE or the Company ), today announced the dosing of the first patient in a Phase...
Globe Newswire·2y ago

Latest LIXT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.